Digitisation | December 08, 2021
Olympus lays out its plans for growth in the medical business
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
Investment in single-use endoscopes, digital solutions, and endoluminal therapies expected
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide
Officials from ACG signed the MoU with the Maharashtra government for the Rs 600 crore investment in the backward region of Marathwada
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Cipla Technologies a subsidiary of Cipla and Pulmatrix had inked a definitive agreement for the co-development and commercialisation of Pulmazole.
The new manufacturing facility will be built at a subsidiary of Adcock Ingram and will commence operation in March 23
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
Torrent Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
Subscribe To Our Newsletter & Stay Updated
